Venclexta 50mg Tablet contains the active ingredient Venetoclax. Venclexta 50mg Tablet is an antineoplastic drug that belongs to the class of BCL-2 inhibitors. It is used to treat adults with certain types of blood cancers, including chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). 

Specifically, it is used in CLL with a 17p deletion and in AML in patients who cannot undergo intensive chemotherapy. Additionally, it can be used in combination with other medications to treat certain types of non-Hodgkin lymphoma.

Venclexta 50mg Tablet works by inhibiting the BCL-2 protein, which helps promote cancer cell death. This action restores the process of apoptosis (programmed cell death) by binding to BCL-2, displacing pro-apoptotic proteins, and initiating mitochondrial outer membrane permeabilization, which triggers cell death.

Do not take Venclexta 50mg Tablet if you are allergic to Venetoclax or any of the other ingredients in the medication. Before starting treatment, inform your doctor if you have kidney problems, a history of infections, or any blood-related disorders like low white blood cell count or low platelet count. 

Ensure that your physician is aware of any past history of Tumor Lysis Syndrome (TLS) or if you are pregnant or planning to become pregnant, as Venclexta may harm the fetus. Venclexta 50mg Tablet should not be used in children or adolescents under the age of 18.

Chronic lymphocytic leukemia (CLL), including CLL with 17p deletion.

Acute myeloid leukemia (AML) in adults who cannot undergo intensive chemotherapy.

Certain types of non-Hodgkin lymphoma, when combined with other medications.

Venclexta 50mg Tablet works as a selective, orally bioavailable small-molecule inhibitor of BCL-2, an antiapoptotic protein. In CLL and AML cells, BCL-2 overexpression supports tumour cell survival and chemotherapy resistance by binding directly to BCL-2, Venclexta 50mg Tablet displaces pro-apoptotic proteins like BIM, triggering mitochondrial outer membrane permeabilization and activating caspases. Nonclinical studies demonstrate venetoclax’s cytotoxic effect on tumor cells overexpressing BCL-2.

Venclexta 50mg Tablet is administered orally. Do not break, chew, or crush the tablets. Follow the prescribed dosing schedule and consult your healthcare provider to determine the correct dosage. If you miss a dose, do not double the dose. Contact your healthcare provider for guidance.

Fatigue

Anemia

Nausea

Diarrhea

Low platelet count (thrombocytopenia)

Low white blood cell count (neutropenia)

Risk of death

Tumor lysis syndrome (TLS)

Kidney failure

Need for dialysis treatment

It is important to inform your healthcare professional about all the medications you are taking, including prescription drugs, over-the-counter medications, nutritional supplements, and herbal products. Some medications may interact with Venclexta 50mg Tablet, potentially affecting their effectiveness or causing side effects.

Keep out of reach of children and pets.

Store Venclexta 50mg Tablet in the original packaging to protect it from moisture.

Avoid direct sunlight.

Store Venclexta 50mg Tablet at a temperature not exceeding 30°C

Venclexta 50mg Tablet can cause serious side effects like Tumor Lysis Syndrome (TLS), neutropenia, and infections, requiring close monitoring and prophylactic treatment, especially during the ramp-up phase. It may also harm the fetus, so women of reproductive potential should avoid pregnancy during treatment. Regular blood counts are essential to detect neutropenia, and live attenuated vaccines should be avoided. Follow your healthcare provider’s instructions carefully, stay hydrated, and notify your doctor immediately if you experience symptoms like fever or unusual tiredness.